Several new targeted drugs have been specifically used to effectively treat HER2-positive breast cancer in the past decade, including the famous HER2-targeted drug trastuzumab (Herceptin) and the second-generation HER2-targeted drug pertuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.